Serum IGF-1 has long been the default readout for confirming that a growth hormone–releasing hormone (GHRH) analogue such as tesamorelin has engaged the somatotropic axis. This review examines a wider panel of emerging biomarkers — imaging, proteomic, transcriptomic, and circulating nucleic-acid signals — that researchers are using to characterize metabolic responses in experimental models and completed clinical cohorts.

The somatotropic axis, from GHRH analogue to metabolic readout

Tesamorelin is a stabilized synthetic analogue of human GHRH. In experimental use it binds pituitary GHRH receptors and augments the pulsatile secretion of endogenous growth hormone (GH), which in turn raises hepatic insulin-like growth factor 1 (IGF-1). The reason a single marker rarely tells the whole story is that the biologically interesting endpoints sit several steps downstream of receptor binding: GH and IGF-1 modulate peripheral lipolysis and hepatic lipid handling, and it is those tissue-level changes — not the hormone concentrations themselves — that researchers ultimately want to quantify.¹

This cascade frames the entire biomarker discussion. A marker can report on any of three tiers: axis engagement (IGF-1), tissue outcome (liver and visceral fat measured by imaging), or the molecular mediators that connect the two (plasma proteins, microRNAs, and enzymes). Because a compound can raise IGF-1 without producing a proportional change in fat depots — and because individuals differ in baseline GH sensitivity — investigators increasingly treat these tiers as complementary rather than interchangeable.⁹

Serum IGF-1: the primary but incomplete surrogate

Serum IGF-1 remains the standard surrogate for confirming that a GHRH analogue has activated the GH axis. It is inexpensive, widely assayed, and rises predictably after administration, which makes it useful for verifying that a peptide preparation is biologically active and for keeping exposure within a physiological window rather than an acromegaly-like range. In a randomized study of tesamorelin among people with HIV on integrase-inhibitor regimens, treatment produced the expected reductions in visceral and hepatic fat and the anticipated pharmacodynamic response was preserved across the cohort.¹

The limitation is interpretive. Analyses of individuals with NAFLD show that hepatic IGF1 messenger RNA can be reduced in more severe steatosis and can relate to glycemic measures independently of circulating IGF-1, meaning that a normal or elevated serum value does not guarantee a favorable tissue-level state.⁹ IGF-binding proteins add further complexity: the same work reported divergent behavior across IGFBP-1, -2, -3, -6, and -7, and showed that GHRH administration shifted several binding proteins in different directions. For research design, the practical consequence is that IGF-1 answers “did the axis respond?” but not “what happened in the liver and adipose tissue?”

Imaging biomarkers: hepatic fat fraction and visceral fat

The most robust human evidence for tesamorelin's metabolic effects comes from imaging endpoints. In a randomized, double-blind trial, tesamorelin reduced liver fat measured by proton magnetic resonance spectroscopy and lowered visceral adipose tissue (VAT) quantified by computed tomography, establishing the two imaging readouts that most later studies adopted.² A subsequent randomized, multicenter trial that used serial liver biopsy reported that tesamorelin reduced hepatic fat and was associated with a lower likelihood of fibrosis progression over 12 months — the strongest histological evidence available for this compound.³

Hepatic fat fraction, whether derived from spectroscopy or proton-density fat-fraction MRI, has become a favored longitudinal marker because it is non-invasive, quantitative, and reproducible across visits, which is difficult to achieve with biopsy. Several features make it attractive for mechanistic research:

• Lipid re-partitioning. Reductions in liver fat in these cohorts occurred alongside decreases in visceral fat, consistent with coordinated depot-level change rather than isolated hepatic effects.²
• Fibrosis linkage. The biopsy trial connected fat reduction to fibrosis-related outcomes, allowing hepatic fat fraction to be interpreted against a histological reference standard.³
• Exposure dependency. Effects were observed over defined treatment windows, so imaging is typically read longitudinally rather than at a single timepoint.³

Tesamorelin is intended within these studies as a research and experimental intervention for HIV-associated fat accumulation; it is not an approved therapy for NAFLD in the general population, and imaging endpoints in these trials are research measures, not clinical treatment targets. Researchers pairing peptide work with reconstitution steps often standardize their diluent handling with a consistent BAC water preparation to reduce technical variability across imaging timepoints.

Proteomic signatures: VEGFA, TGFβ1, and CSF1

Plasma proteomics offers a middle tier between axis activation and gross imaging change. In a focused proteomic analysis nested within a randomized tesamorelin trial, investigators measured nine plasma proteins selected from differentially regulated hepatic gene sets. Tesamorelin produced significant reductions in vascular endothelial growth factor A (VEGFA), transforming growth factor beta 1 (TGFβ1), and macrophage colony-stimulating factor 1 (CSF1) relative to placebo.⁴ Importantly, the magnitude of the VEGFA and CSF1 declines correlated with the decline in NAFLD activity score, and the TGFβ1 and CSF1 reductions tracked with a gene-level fibrosis score — providing a plausible bridge between a circulating protein and a tissue-level outcome.

These proteomic shifts did not arise in isolation. A companion transcriptomic study reported that tesamorelin downregulated hepatic gene sets involved in inflammation, tissue repair, and cell division, which is the biological rationale for measuring the corresponding plasma proteins in the first place.⁵ The interpretive caution is that plasma proteins are influenced by many processes beyond a single peptide, so mass-spectrometry or targeted immunoassay panels are used to isolate treatment-associated changes from background variation. Proteomic markers such as VEGFA and TGFβ1 are therefore best read as correlative signals within controlled designs rather than as standalone efficacy proof.

Circulating microRNAs as upstream signals

Circulating microRNAs are studied as early molecular reporters of hepatic and metabolic status because they can shift before structural changes become detectable on imaging. miR-122 is the most liver-enriched microRNA and, together with markers such as miR-192 and miR-223, has been repeatedly associated with steatosis and NAFLD severity across human cohorts.¹¹ In adolescents with severe obesity, circulating microRNA profiles differed with NAFLD status, reinforcing the idea that these species index hepatic lipid handling and inflammatory signaling.¹²

The honest caveat is that most microRNA data come from observational NAFLD populations rather than from tesamorelin trials specifically. A microRNA such as miR-122 is a candidate for capturing upstream response during early experimental phases, and it may complement imaging by flagging molecular change sooner, but a direct, replicated demonstration that tesamorelin moves a defined microRNA panel is not yet established in the peer-reviewed record. Researchers treat microRNA readouts as exploratory hypotheses to be validated against imaging and histology, not as confirmed efficacy markers.

Liver enzymes, FGF21, and inflammatory markers

Beyond imaging and proteomics, several accessible blood markers have shown coherent behavior in tesamorelin cohorts. Among participants with elevated baseline transaminases, those who achieved a clinically meaningful visceral-fat reduction experienced greater decreases in ALT and AST than non-responders, linking depot change to routine liver chemistry.⁸ Fibroblast growth factor 21 (FGF21), a hepatokine elevated in fatty liver, decreased in association with reductions in liver fat during tesamorelin treatment — and the analysis suggested the peptide improves liver fat through pathways other than raising FGF21, illustrating how a marker can move without being the mechanistic driver.⁷

On the inflammatory axis, a study of GHRH administration in HIV-associated NAFLD reported reductions in circulating markers of immune activation that paralleled effects on hepatic immune pathways, consistent with a lower systemic inflammatory tone accompanying visceral-fat loss.⁶ These markers — enzymes, hepatokines, and immune-activation indices — are attractive because they are inexpensive and longitudinally repeatable, but each is nonspecific on its own and is most informative when interpreted alongside imaging.

Muscle–adipose cross-talk

Because GH secretagogues act on both fat and lean tissue, some researchers extend biomarker panels to skeletal muscle. A secondary analysis of two randomized tesamorelin trials found that, among visceral-fat responders, tesamorelin was associated with increased muscle density and modest increases in muscle area across several trunk muscle groups — a signal that fat loss did not come at the expense of measurable muscle quality in that dataset.¹⁰ This makes muscle imaging a candidate readout for studying how ectopic-fat reduction and lean-tissue metabolism interact.

Myostatin, a negative regulator of muscle mass, is frequently proposed as a circulating marker of this cross-talk on the strength of general GH physiology, in which GH activity and myostatin signaling are inversely related. It is worth stating plainly that a specific, replicated tesamorelin–myostatin dataset is not established in the primary literature reviewed here; the current muscle evidence rests on imaging-based density and area measures rather than on a validated myostatin panel.¹⁰ Investigators exploring GH-axis peptides such as sermorelin alongside tesamorelin often pair any myostatin measurement with direct markers of protein turnover to avoid over-reading a single circulating value.

Building an integrated biomarker panel

The recurring theme across these categories is that no single marker resolves metabolic response. IGF-1 confirms axis engagement; imaging quantifies the tissue outcome; proteomics, enzymes, and microRNAs describe the mediators and the tempo of change. Combining tiers reduces interpretive bias and lets a research team distinguish generalized change from targeted visceral and hepatic remodeling. The table below summarizes how the main candidate markers map onto modality and evidence strength within tesamorelin research.

For laboratories sourcing material for this kind of work, the upstream variable that most often undermines reproducibility is the peptide itself. Consistent purity and transparent analytical documentation allow observed marker shifts to be attributed to experimental conditions rather than to lot-to-lot variation, which is the entire premise of a multi-marker panel.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.